Synthetic medial meniscus prosthesis may improve outcomes at 3 years vs. standard of care
Click Here to Manage Email Alerts
Key takeaways:
- The meniscus prosthesis group had significant improvements in KOOS overall and pain scores.
- The meniscus prosthesis group had less symptoms, better activities of daily living and better quality of life.
WASHINGTON — Results showed patients who received a meniscus replacement prosthesis had clinically meaningful improvement in patient-reported outcome scores at 3 years compared with patients who received nonsurgical standard of care.
“The NUsurface meniscus replacement device works well compared to meniscus and allograft transplantation,” Christian Lattermann, MD, said in his presentation at the American Orthopaedic Society for Sports Medicine Annual Meeting. “[It is] certainly less complicated, none of the study patients were worse off and, in fact, for most of them, they had significant improvements.”
Lattermann and colleagues randomly assigned patients who were aged between 30 and 75 years who previously underwent a meniscectomy and still experienced knee pain to receive either a synthetic medial meniscus replacement prosthesis (n=61; NUsurface Meniscus Implant, Active Implants) or nonsurgical standard of care (n=66).
“The definition of success was based on a difference of 20 points under KOOS for pain and overall [scores] for the nonoperative group and no additional knee surgery required,” Lattermann said. “The subsets for the NUsurface treatment group were the same in terms of pain in KOOS and no implant dislocation or fracturing or implant removals.”
Lattermann said patients in the NUsurface group had significant improvements in both KOOS overall scores and pain scores compared with the nonsurgical standard of care group. He added patients in the NUsurface group had less symptoms, better activities of daily living, higher activity scores and better quality of life.
“Controls failed at twice the rate, but the NUsurface failure rate, however, was not zero. It’s at 16%, which is a problem because that needs to be addressed with the FDA,” Lattermann said.
Collapse
Hershman E, et al. Paper 33. Presented at: American Orthopaedic Society for Sports Medicine Annual Meeting; July 12-16, 2023; Washington, D.C.
Read more about
Click Here to Manage Email Alerts